One question on HIV prevention: Will patients take their meds?

Patients who know they're sick have trouble sticking to their medication regimens, as anyone who works to boost drug adherence knows. So, can people at risk of HIV infection be trusted to continue taking high-powered antiretrovirals to keep from getting the disease? News | Report

Suggested Articles

Merck & Co. set out to answer the question of whether lung cancer patients with KRAS mutations respond as well to Keytruda as others do.

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.